Online inquiry

IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11349MR)

This product GTTS-WQ11349MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Neuromyelitis optica (NMO) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ11349MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15072MR IVTScrip™ mRNA-Anti-KDR, SSS-23(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SSS-23
GTTS-WQ1056MR IVTScrip™ mRNA-Anti-TNFRSF10B, ABBV-621(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABBV-621
GTTS-WQ6035MR IVTScrip™ mRNA-Anti-IL6, CNTO 136(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CNTO 136
GTTS-WQ7713MR IVTScrip™ mRNA-Anti-ERBB2, GEXMab73(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GEXMab73
GTTS-WQ5202MR IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CAT-8015
GTTS-WQ4701MR IVTScrip™ mRNA-Anti-MAPT, BMS-986168(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BMS-986168
GTTS-WQ13894MR IVTScrip™ mRNA-Anti-PDGFRB, REGN-2176(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-2176
GTTS-WQ1848MR IVTScrip™ mRNA-Anti-IL17A, AG1-25(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AG1-25
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW